Jefferies raised the firm’s price target on Bristol Myers (BMY) to $51 from $49 and keeps a Hold rating on the shares ahead of Bayer (BAYRY) presenting asundexian OCEANIC-AF data at ESC. While the firm remains on the sideline regarding Bristol’s FXIa inhibitor milvexian, it is “incrementally bullish” that Bayer may have underdosed asundexian in the OCEANIC Phase 3 study and the firm is upping its Milvexian peak-sales, pre profit share, forecast to $2.8B from $1.3B, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers price target raised to $42 from $41 at Barclays
- Bristol Myers announces FDA accepted supplemental BLA for Opdivo plus Yervoy
- Neurocrine price target raised to $189 from $177 at Jefferies
- Bristol Myers announces EMA validation to expand Brevanzi indication
- Healthcare Stocks Rise despite Medicare Price Cuts for Their Drugs